



AOXIN Q & M DENTAL GROUP LIMITED
 (Company Registration Number 201110784M)
 (Incorporated in the Republic of Singapore)

REALLOCATION AND UPDATE ON USE OF PROCEEDS FROM THE INITIAL PUBLIC OFFERING

The Board of Directors (the “**Board**”) of Aoxin Q&M Dental Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s offer document dated 18 April 2017 in connection with its initial public offering (“**IPO**”) on the Catalist board of the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the Company’s FY2017 Annual Report, and wishes to provide an update on the use of proceeds raised from the IPO (the “**IPO Proceeds**”).

After taking into consideration, *inter alia*, review of the Group’s cash flow and expansion plans, the Board has decided to re-allocate S\$2.7 million of the IPO Proceeds originally allocated for the funding of enhancement of infrastructure and working capital purposes to the expansion of the Group’s business through organic growth, mergers and acquisitions, joint ventures and partnerships (the “**Reallocation**”). The Board is of the view that the Reallocation of the IPO Proceeds is in the best interests of the Group and its shareholders as it is in line with the Group’s expansion plans.

The following table summarises the Reallocation of IPO Proceeds:

INTENDED USE OF IPO PROCEEDS	AMOUNT ALLOCATED (S\$’ million)	AMOUNT AFTER REALLOCATION (S\$’ million)	AMOUNT UTILISED (S\$’ million)	BALANCE OF IPO PROCEEDS (S\$’ million)
Expansion of business through organic growth, mergers and acquisitions, joint ventures and partnerships	6.4	9.1	(6.9)	2.2
Enhancement of infrastructure and working capital purposes	2.7	-	-	-
Total	9.1	9.1	(6.9)	2.2

The Company will make periodical announcements via SGXNet on the utilisation of the balance of the IPO Proceeds as and when they are materially disbursed and will also provide a status report on the use of such proceeds in the annual reports of the Company.

By Order of the Board
Aoxin Q&M Dental Group Limited

Cheong Yew Meng
Chief Financial Officer
8 June 2018

For more information please contact:

Chief Financial Officer

Cheong Yew Meng | Tel: (65) 6235 1188 | Email: yewmeng@aoxin.sg

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, SAC Capital Private Limited, for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Company's Sponsor has not independently verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Alicia Sun (Tel: (65) 6532 3829) at 1 Robinson Road, #21-02 AIA Tower, Singapore 048542.